Papilloma virus-like particles, fusion proteins as well as processes for their production
CA 2202090 C · Owner: Loyola University Of Chicago · Inventors: Zhou, Jian; Gissmann, Lutz; Heinrich, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Recombinant papilloma virus-like particles result from the expression of viral structural proteins L1 and/or L2 in which one or several sections of the L1 and/or L2 protein are deleted. The ability to form virus-like particles is at least the same as, preferably higher than, that of native reproduction and/or in vitro production processes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 9, 1995 and granted April 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 9, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 9, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.